Following the outbreak of Covid-19, Denmark's capacity for producing vaccines has been a frequent case of debate. Now, this challenge is being addressed in the new life science strategy which the Danish government presented on Friday morning.
The new strategy further states that Denmark wishes to form a "partnership with the life science industry on strengthened access to vaccines".
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.